Literature DB >> 14745763

Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry.

Nils v Neuhoff1, Thorsten Kaiser, Stefan Wittke, Ronald Krebs, Andrew Pitt, Aurea Burchard, Astrid Sundmacher, Brigitte Schlegelberger, Walter Kolch, Harald Mischak.   

Abstract

The discovery of biomarkers is currently attracting much interest as it harbors great potential for the diagnosis and monitoring of human diseases. Here we have used two advanced mass spectroscopy based technologies, surface enhanced laser desorption ionization (SELDI-MS) and capillary electrophoresis/mass spectrometry (CE/MS), to obtain proteomic patterns of urine samples from patients suffering from membranous glomerulonephritis (MGN) and healthy volunteers. The results indicate that CE/MS analysis is able to display a rich and complex pattern of polypeptides with high resolution and high mass accuracy. In order to analyze these patterns, the MosaiqueVisu software was developed for peak identification, deconvolution and the display of refined maps in a three-dimensional format. The polypeptide profiles obtained with SELDI-MS from the same samples are much sparser and show lower resolution and mass accuracy. The SELDI-MS profiles are further heavily dependent on analyte concentration. SELDI-MS analysis identified three differentially expressed polypeptides, which are potential biomarkers that can distinguish healthy donors from patients with MGN. In contrast, approximately 200 potential biomarkers could be identified by CE/MS. Thus, while SELDI-MS is easy to use and requires very little sample, CE/MS generates much richer data sets that enable an in-depth analysis. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745763     DOI: 10.1002/rcm.1294

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  59 in total

Review 1.  Teaching molecular genetics: Chapter 3--Proteomics in nephrology.

Authors:  Patricia J T A Groenen; Lambert P W J van den Heuvel
Journal:  Pediatr Nephrol       Date:  2006-03-30       Impact factor: 3.714

Review 2.  Mass spectrometry based proteomics in urine biomarker discovery.

Authors:  Dan Theodorescu; Harald Mischak
Journal:  World J Urol       Date:  2007-08-17       Impact factor: 4.226

3.  High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine.

Authors:  Harald Mischak; Bruce A Julian; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2007-07-10       Impact factor: 3.494

4.  Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Marion Haubitz; David M Good; Alexander Woywodt; Hermann Haller; Harald Rupprecht; Dan Theodorescu; Mohammed Dakna; Joshua J Coon; Harald Mischak
Journal:  Mol Cell Proteomics       Date:  2009-06-28       Impact factor: 5.911

5.  A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves.

Authors:  Bénédicte Buffin-Meyer; Marcin Tkaczyk; Małgorzata Stańczyk; Benjamin Breuil; Justyna Siwy; Krzysztof Szaflik; Tomasz Talar; Justyna Wojtera; Waldemar Krzeszowski; Stéphane Decramer; Julie Klein; Joost P Schanstra
Journal:  Pediatr Nephrol       Date:  2019-11-07       Impact factor: 3.714

6.  Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis.

Authors:  Constantin von zur Muhlen; Eric Schiffer; Christine Sackmann; Petra Zürbig; Irene Neudorfer; Andreas Zirlik; Nay Htun; Alexander Iphöfer; Lothar Jänsch; Harald Mischak; Christoph Bode; Yung C Chen; Karlheinz Peter
Journal:  Mol Cell Proteomics       Date:  2012-02-27       Impact factor: 5.911

7.  Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

Authors:  Justyna Siwy; Joost P Schanstra; Angel Argiles; Stephan J L Bakker; Joachim Beige; Petr Boucek; Korbinian Brand; Christian Delles; Flore Duranton; Beatriz Fernandez-Fernandez; Marie-Luise Jankowski; Mohammad Al Khatib; Thomas Kunt; Maria Lajer; Ralf Lichtinghagen; Morten Lindhardt; David M Maahs; Harald Mischak; William Mullen; Gerjan Navis; Marina Noutsou; Alberto Ortiz; Frederik Persson; John R Petrie; Johannes M Roob; Peter Rossing; Piero Ruggenenti; Ivan Rychlik; Andreas L Serra; Janet Snell-Bergeon; Goce Spasovski; Olivera Stojceva-Taneva; Matias Trillini; Heiko von der Leyen; Brigitte M Winklhofer-Roob; Petra Zürbig; Joachim Jankowski
Journal:  Nephrol Dial Transplant       Date:  2014-03-02       Impact factor: 5.992

8.  The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease.

Authors:  Petra Zürbig; Stéphane Decramer; Mohammed Dakna; Justyna Jantos; David M Good; Joshua J Coon; Flavio Bandin; Harald Mischak; Jean-Loup Bascands; Joost P Schanstra
Journal:  Proteomics       Date:  2009-04       Impact factor: 3.984

9.  Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

Authors:  Sten Andersen; Harald Mischak; Petra Zürbig; Hans-Henrik Parving; Peter Rossing
Journal:  BMC Nephrol       Date:  2010-11-01       Impact factor: 2.388

10.  Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology.

Authors:  David M Maahs; Justyna Siwy; Angel Argilés; Marie Cerna; Christian Delles; Anna F Dominiczak; Nathalie Gayrard; Alexander Iphöfer; Lothar Jänsch; George Jerums; Karel Medek; Harald Mischak; Gerjan J Navis; Johannes M Roob; Kasper Rossing; Peter Rossing; Ivan Rychlík; Eric Schiffer; Roland E Schmieder; Thomas C Wascher; Brigitte M Winklhofer-Roob; Lukas U Zimmerli; Petra Zürbig; Janet K Snell-Bergeon
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.